Free tool
FAERS Monitor: Tezruly
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 218139 or its brand name (Tezruly, Terazosin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
7,627
Serious
5,231
69% of reports
Hospitalization
2,734
Death reported
857
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective489
- fatigue478
- diarrhoea402
- dizziness397
- dyspnoea395
- asthenia367
- acute kidney injury357
- death344
- chronic kidney disease320
- off label use315
- renal failure303
- nausea296
- fall288
- pain274
- pneumonia261
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 9 |
| 2005 | 235 |
| 2006 | 52 |
| 2007 | 11 |
| 2008 | 15 |
| 2009 | 45 |
| 2010 | 35 |
| 2011 | 138 |
| 2012 | 190 |
| 2013 | 417 |
| 2014 | 517 |
| 2015 | 754 |
| 2016 | 751 |
| 2017 | 703 |
| 2018 | 686 |
| 2019 | 674 |
| 2020 | 549 |
| 2021 | 484 |
| 2022 | 353 |
| 2023 | 323 |
| 2024 | 251 |
| 2025 | 259 |
| 2026 | 175 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,532 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| chronic kidney diseaseSignal | 320 | 11.7 | 10.5 | 3,106 |
| acute kidney injurySignal | 357 | 6.4 | 5.8 | 1,645 |
| renal failureSignal | 303 | 6.3 | 5.6 | 1,352 |
| astheniaSignal | 367 | 2.7 | 2.4 | 396 |
| fallSignal | 288 | 2.4 | 2.1 | 234 |
| pneumoniaSignal | 261 | 2.2 | 2.0 | 177 |
| dizzinessSignal | 397 | 2.2 | 2.0 | 263 |
| dyspnoea | 395 | 1.9 | 1.7 | 179 |
| diarrhoea | 402 | 1.7 | 1.6 | 124 |
| fatigue | 478 | 1.7 | 1.6 | 140 |
| pain | 274 | 1.2 | 1.1 | 12 |
| death | 344 | 1.1 | 1.0 | 3 |
| nausea | 296 | 1.0 | 0.9 | 0 |
| drug ineffective | 489 | 1.0 | 0.9 | 0 |
| off label use | 315 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.